What Does Wegovy’s Launch in China Mean as Biosimilar Competition Emerges?

Late last month, China’s National Medical Products Administration approved Novo Nordisk’s blockbuster GLP-1 weight loss drug Wegovy (semaglutide), opening up another multimillion-dollar market for the Danish pharma. However, the approval comes at a time when biosimilar competition in China is ramping up.